McLean hospital study examines the cost-effectiveness of esketamine

July 13, 2020

Highlights: * Study estimated the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression * Researchers employed a decision-analytic model to simulate the effects of treatment with esketamine versus oral antidepressants from both societal and health care sector perspectives * Study concluded that the price of esketamine must fall by more than 40% to be cost-effective for management of treatment-resistant depression in the United States

A paper authored by Psychiatric Services.

The study compared the costs and benefits of esketamine, an antidepressant approved by the U.S. Food and Drug Administration (FDA) last year for use in treatment-resistant major depressive disorder. Unlike

Lead author Eric L. Ross, MD, reported that "most medications don't work as well for people with treatment-resistant depression." However, he said, "Esketamine has been effective in a population where many other treatments haven't worked."

Ross said, "I want people to use esketamine, but it's important that it be cost-effective. I don't want it to put a real strain on our mental health care system."

To estimate the cost-effectiveness of the drug, Ross and his colleagues used a "decision-analytic model" to simulate the effects of treatment with esketamine versus oral antidepressants over five years. The model looked at both societal and health care sector perspectives of using the drug.

Ross explained that the study built on previous investigations of esketamine but added information about cost. Also, he said, the model accounted for issues such as "How much does it cost to have uncontrolled depression?" and "How much does it impact your quality of life?"

The simulations found that, over five years, esketamine was projected to improve quality of life by increasing time in remission for patients. Societal costs and health care sector costs, however, were projected to go up substantially. The authors estimated a greater than 95% likelihood that intranasal esketamine would not be cost-effective in the United States, according to commonly applied standards. Also, they concluded that the price of esketamine must fall by more than 40% from its current price of approximately $240 per dose to be cost-effective for the management of treatment-resistant depression in the U.S.

"Esketamine is too expensive, but it does work," Ross asserted. "The question now is 'How do we get the price down?'"

Ross said that he hopes the paper will encourage policymakers, insurers, and health care leaders to work to reduce the price of esketamine and make it more available to those in need. "At the end of the day, it's not about saving money," he said. "The goal is to make sure we're getting the most clinical benefit we can for the money we spend."
-end-
FUNDING: This study was supported by Research Training and Career Development grant R25-MH-094612 from the National Institute of Mental Health to Dr. Ross. The National Institute of Mental Health did not participate in the design of the study, the analysis and interpretation of the data, or the preparation and submission of the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ABOUT McLEAN HOSPITAL:
https://www.mcleanhospital.org/ or follow us on
McLean Hospital

Related Esketamine Articles from Brightsurf:

McLean hospital study examines the cost-effectiveness of esketamine
A paper authored by researchers from McLean Hospital has determined that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use.

Ef­fects of rapid-act­ing an­ti­de­press­ants con­sol­id­ated in sleep?
Ketamine alleviates depressive symptoms within hours, with the most significant change typically seen a day after its administration.

Side effects mild, brief with single antidepressant dose of intravenous ketamine
Researchers found that a single, low-dose ketamine infusion was relatively free of side effects for patients with treatment-resistant depression.

Simple injection of air proves successful in releasing child's tongue trapped in bottle, inspired by opening a wine bottle
A relatively simple injection of air has proved successful in releasing a 7-year-old boy's tongue that became entrapped in a juice bottle, says new research published in the latest edition of the European Journal of Anaesthesiology (the official journal of the European Society of Anaesthesiology).

Study supports effectiveness of new fast-acting antidepressant, esketamine nasal spray
New research supports the effectiveness and safety of esketamine nasal spray in treating depression in people who have not responded to previous treatment.

Study shows fast-acting benefits of ketamine for depression and suicidality
A nasal spray formulation of ketamine shows promise in the rapid treatment of symptoms of major depression and suicidal thoughts, according to a new study published online today in The American Journal of Psychiatry (AJP).

Antidepressant response within hours? Experts weigh evidence on ketamine as fast-acting treatment for depression in Harvard Review of Psychiatry
Recent studies suggest that ketamine, a widely used anesthetic agent, could offer a wholly new approach to treating severe depression -- producing an antidepressant response in hours rather than weeks.

Read More: Esketamine News and Esketamine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.